Cardiff Oncology Files Definitive Proxy Statement
Ticker: CRDF · Form: DEFA14A · Filed: Apr 30, 2025 · CIK: 1213037
| Field | Detail |
|---|---|
| Company | Cardiff Oncology, Inc. (CRDF) |
| Form Type | DEFA14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, annual-meeting
Related Tickers: CRDF
TL;DR
CRDF filed its proxy statement, get ready for the shareholder meeting.
AI Summary
Cardiff Oncology, Inc. (CRDF) filed a Definitive Proxy Statement (DEFA14A) on April 30, 2025. This filing is related to the company's annual meeting and is not a preliminary statement. The company, formerly known as Trovagene, Inc., is based in San Diego, CA.
Why It Matters
This filing is a standard procedural document for public companies, indicating that Cardiff Oncology is preparing for its annual shareholder meeting where key corporate decisions are made.
Risk Assessment
Risk Level: low — This is a routine regulatory filing and does not contain new financial information or strategic changes that would inherently increase risk.
Key Players & Entities
- Cardiff Oncology, Inc. (company) — Registrant
- Trovagene, Inc. (company) — Former company name
- San Diego, CA (location) — Business address
FAQ
What type of SEC filing is this?
This is a Definitive Proxy Statement (DEFA14A).
Who is the filing company?
The filing company is Cardiff Oncology, Inc.
When was this filing made?
The filing was made on April 30, 2025.
What is the company's former name?
The company was formerly known as Trovagene, Inc.
What is the company's business address?
The company's business address is 11055 Flintkote Avenue, San Diego, CA 92121.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 30, 2025 regarding Cardiff Oncology, Inc. (CRDF).